Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart or kidney disease.

Whether you work from home regularly or need to print school assignments for the kids, having a reliable home printer can make all the difference. With a wide range of options available, it's ...

LIKE MANY OTHER PROVIDERS, NP TO-GO OFFERED THEIR PATIENTS COPYCAT VERSIONS OF THE SEMAGLUTIDE FROM COMPOUNDING PHARMACIES, BUT THAT HAS COME TO A HALT AFTER THE FDA DECLARED THERE WAS NO LONGER A ...

Installing a new cartridge is something of a rite of passage for turntable owners. It’s a skill that once was common, but now seems to be considered some kind of black art by many. In reality, it’s ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Share on Pinterest Common antidiabetes drugs could help lower Alzheimer’s risk, increasing evidence suggests. Image credit: mbbirdy/Getty Images. A new study investigates the relationship ...

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...

Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat type 2 diabetes and Wegovy for managing overweight or obesity. GLP-1 is a hormone produced by the intestines.

The Ministry of Health has registered the seventh semaglutide drug from Russian pharmaceutical companies, an analogue of Novo Nordisk’s blockbuster Ozempiс. The new drug, Segluria, is manufactured by ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).